Mustang and the bubble boy bubble
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.